Role of 18F-fluorodeoxyglucose PET/CT in Recurrent Ovary Cancer.
- Author:
Joo Hyun O
1
;
Ie Ryung YOO
;
Woo Hee CHOI
;
Won Hyoung LEE
;
Sung Hoon KIM
;
Soo Kyo CHUNG
Author Information
1. Department of Radiology, The Catholic University of Korea, Seoul, Korea. iryoo@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
18F-FDG;
PET/CT;
ovary cancer;
recurrence
- MeSH:
Biopsy;
Female;
Fluorodeoxyglucose F18;
Follow-Up Studies;
Humans;
Ovarian Neoplasms;
Ovary;
Pelvis;
Recurrence;
Sensitivity and Specificity;
Biomarkers, Tumor
- From:Nuclear Medicine and Molecular Imaging
2008;42(3):209-217
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To date, anatomical imaging modalities of the pelvis and tumor markers have been the mainstay of surveillance for recurrent ovary cancer. This study aimed to assess the role of 18F-FDG PET/CT in evaluation of ovary cancer recurrences, especially in comparison with enhanced CT and tumor marker CA 125. Materials and METHODS: 73 patients who had PET/CT scan for restaging of confirmed ovary cancer, and additional imaging with enhanced CT of the pelvis within one month were included. CA 125 level was available in all patients. From the PET/CT images, maximum standard uptake values (SUVmax) of suspected recurrence sites were recorded. Confirmation was available through re-operation or biopsy in 26 cases, and clinical assessment with series of follow-up images in 47. RESULTS: PET/CT had 93% sensitivity and 88% specificity for detecting recurrent ovary cancer. Enhanced CT of pelvis had sensitivity and specificity of 83% and 88%, and CA 125 50% and 95%. CONCLUSION: PET/CT has higher sensitivity for detecting recurrent ovary cancer compared to enhanced CT though the differences were not significant. PET/CT has significantly higher sensitivity than CA 125. However, the three tests all agreed in only 43% of the recurrence cases, and recurrence should be suspected when any of the tests, especially PET/CT, show positive findings.
